Creating a new NHS England: NHS Digital and NHS England have now merged. Health Education England will join us in April 2023. Learn more.
Contents
- Amiodarone for patients within adult services
- Atomoxetine for patients within adult services
- Azathioprine and mercaptopurine for patients within adult services (non-transplant indications)
- Ciclosporin (oral) for patients within adult services (non-transplant indications)
- Dexamfetamine for patients within adult services
- Dronedarone for patients in adult services
- Guanfacine for patients within adult services
- Hydroxycarbamide for myeloproliferative disorders and sickle cell disease for patients within adult services
- Hydroxychloroquine for patients within adult services
- Leflunomide for patients within adult services
- Lisdexamfetamine for patients within adult services
- Lithium for patients within adult services
- Methotrexate (oral and subcutaneous) for patients in adult services (excluding cancer care)
- Methylphenidate in adult services
- Mycophenolate mofetil and mycophenolic acid for patients within adult services (non-transplant indications)
- Riluzole for patients within adult services
- Sulfasalazine for patients within adult services
- Valproate medicines for patients of child-bearing potential – shared care protocol to reflect updated safety advice for all prescribers
Document
Document
Document
Document
Document
Document
Document
Hydroxycarbamide for myeloproliferative disorders and sickle cell disease for patients within adult services
Document
Document
Document
Document
Document
Document
Document
Mycophenolate mofetil and mycophenolic acid for patients within adult services (non-transplant indications)
Document
Document
Document
Valproate medicines for patients of child-bearing potential – shared care protocol to reflect updated safety advice for all prescribers
The Valproate shared care protocol is being reviewed and updated in light of the recent MHRA update